[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608944":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":19,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":19,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":19,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Jemincare","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"JMKX005425","EXPERIMENTAL","Subjects will take a pre-specified dose of JMKX005425.",[13],"Drug: JMKX005425",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","JMKX005425 administered orally.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Lin Shen","Peking University Cancer Hospital & Institute","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Lu Chen","CONTACT","+86 17717684840","chenlu5@jeyoupharma.com",[32],{"facility":33,"status":34,"city":35,"state":19,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing Cancer Hospital","RECRUITING","Beijing","100142","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":22,"role":28,"phone":47,"phoneExt":19,"email":48},"+86 010-88196561","doctorshenlin@sina.cn",{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100608944","phase-1-a-study-of-jmkx005425-in-patients-with-msi-hdmmr-advanced-solid-tumors-100608944",false,"NCT07208136","A Study of JMKX005425 in Patients With MSI-H\u002FdMMR Advanced Solid Tumors","An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX005425 Tablets in Subjects With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors","Inclusion Criteria:\n\n1. Have a microsatellite instability-high (MSI) and\u002For mismatch repair deficiency (dMMR), histologically or cytologically documented advanced solid tumor.\n2. Has at least one measurable lesion per RECIST v1.1.\n3. Has a life expectancy of ≥ 12 weeks.\n4. Adequate organ function.\n\nExclusion Criteria:\n\n1. Toxicities from prior anti-tumor therapy has not recovered to Grade 1 or below per CTCAE v5.0.\n2. History of prior malignancy in the past 3 years, with the exception of curatively treated malignancies.\n3. Has the dysphagia, or impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drug.\n4. Has the severe chronic or active infection\n5. Has a history of severe cardiovascular disease.\n6. Subject is pregnant or breastfeeding.","ALL","18 Years","80 Years",{"count":62,"type":63},102,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and\u002For mismatch repair deficiency (dMMR) advanced solid tumors.",[69],"Advanced Solid Tumors","2025-11-27",{"date":72,"type":73},"2025-12-01","ACTUAL",{"date":75,"type":73},"2025-10-22",{"date":77,"type":63},"2028-12",{"name":5,"class":6},1]